Salta al contenuto principale
Passa alla visualizzazione normale.

GIUSEPPE CABIBBO

Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part I - Surgical treatments

  • Autori: Cabibbo, Giuseppe; Daniele, Bruno; Borzio, Mauro; Casadei-Gardini, Andrea; Cillo, Umberto; Colli, Agostino; Conforti, Massimiliano; Dadduzio, Vincenzo; Dionisi, Francesco; Farinati, Fabio; Gardini, Ivan; Giannini, Edoardo Giovanni; Golfieri, Rita; Guido, Maria; Mega, Andrea; Minozzi, Silvia; Piscaglia, Fabio; Rimassa, Lorenza; Romanini, Laura; Pecorelli, Anna; Sacco, Rodolfo; Scorsetti, Marta; Viganò, Luca; Vitale, Alessandro; Trevisani, Franco
  • Anno di pubblicazione: 2023
  • Tipologia: Articolo in rivista
  • OA Link: http://hdl.handle.net/10447/619413

Abstract

: Worldwide, hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death. The remarkable improvements in treating HCC achieved in the last years have increased the complexity of HCC management. Following the need to have updated guidelines on the multidisciplinary treatment management of HCC, the Italian Scientific Societies involved in the management of this cancer have promoted the drafting of a new dedicated document. This document was drawn up according to the GRADE methodology needed to produce guidelines based on evidence. Here is presented the first part of guidelines, focused on the multidisciplinary tumor board of experts and surgical treatments of HCC.